---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References"
description: "Reference list for the formulary evidence report on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C. 196 cited documents."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References

<a id="references"></a>

## 5 References

1. [Agrawal et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9992339/)
2. [Agrawal et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12818573/)
3. [Albert et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37201244/)
4. [Aqneursa prescribing information (2026)](https://www.aqneursa.com/wp-content/prescribing-information.pdf)
5. [Aston et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6803578/)
6. [Beren Therapeutics ACMG data press release (2026)](https://www.berentx.com/news/beren-therapeutics-presents-data-supporting-the-efficacy-of-adrabetadex-in-infantile-onset-npc-at-2026-acmg-clinical-genetics-meeting/)
7. [Beren Therapeutics Breakthrough Therapy designation press release (2025)](https://www.berentx.com/news/adrabetadex-receives-breakthrough-designation-by-fda/)
8. [Beren Therapeutics CNS data press release (2026)](https://www.berentx.com/news/beren-therapeutics-presents-new-adrabetadex-data-showing-preservation-of-neurological-function-for-more-than-10-years-in-children-with-infantile-onset-npc/)
9. [Beren Therapeutics financing press release (2026)](https://www.berentx.com/news/beren-secures-300m-financing-to-support-the-potential-commercial-launch-of-adrabetadex/)
10. [Beren Therapeutics LEMBAZ approval community update (2026)](https://www.berentx.com/news/community-update-lembaz-adrabetadex-is-approved/)
11. [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)
12. [Beren Therapeutics NDA acceptance press release (2026)](https://www.berentx.com/news/adrabetadex-nda-accepted-priority-review-npc/)
13. [Beren Therapeutics NDA submission community letter (2025)](https://www.berentx.com/news/adrabetadex-new-drug-application-fda-filing-december-2025/)
14. [Beren Therapeutics NDA submission press release (2025)](https://www.berentx.com/news/adrabetadex-nda-submitted-npc/)
15. [Beren Therapeutics October 2024 community update (2024)](https://www.berentx.com/news/npc-community-update-october-2024/)
16. [Beren Therapeutics October 2025 community update (2025)](https://www.berentx.com/news/npc-community-update-october-2025/)
17. [Beren Therapeutics patent estate press release (2026)](https://www.berentx.com/news/beren-therapeutics-expands-cyclodextrin-intellectual-property-estate-with-eight-new-u-s-issued-patents/)
18. [Beren Therapeutics review extension press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-fda-extension/)
19. [Beren Therapeutics September 2024 community update (2024)](https://www.berentx.com/news/npc-community-update-september-2024/)
20. [Beren Therapeutics test for NPC press release (2026)](https://www.berentx.com/news/beren-therapeutics-launches-test-for-npc-to-help-identify-people-with-niemann-pick-disease-type-c-who-remain-undiagnosed/)
21. [Beren Therapeutics webinar community update (2026)](https://www.berentx.com/news/npc-webinar-highlights-path-forward-february-2026/)
22. [Berry-Kravis et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5857219/)
23. [Berry-Kravis et al. (2025)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2025_ANA_Poster_Survival.pdf)
24. [Berry-Kravis et al. (2026a)](https://medical.berentx.com/wp-content/uploads/2026/05/Beren-WorldSymp-2026-Survival-NPCCSS-LB-Poster-01.30.2026_FINAL.pdf)
25. [Berry-Kravis et al. (2026b)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2026_WordSymp_Poster_Biomarkers.pdf)
26. [Berry-Kravis et al. (2026c)](https://medical.berentx.com/wp-content/uploads/2026/03/BerryKravis_2026_ACMG_Oral_Survival-NPCCSS-Biomarkers.pdf)
27. [Berry-Kravis et al. (2026d)](https://pubmed.ncbi.nlm.nih.gov/42551329/)
28. [Berry-Kravis et al. (2026e)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-BaselineNPCCSS_08Oct26_FINAL.pdf)
29. [Berry-Kravis et al. (2026f)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-EarlyTx_08Oct26_FINAL.pdf)
30. [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf)
31. [Bianconi et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6535124/)
32. [Bolton et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8842861/)
33. [Bonney et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20393800/)
34. [Bountouvi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8195555/)
35. [Breen et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23219289/)
36. [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)
37. [Bremova-Ertl et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8361244/)
38. [Bremova-Ertl et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38294974/)
39. [Burchard et al. (2026a)](https://medical.berentx.com/wp-content/uploads/2026/05/APMRF2026-P18.1-MOA.pdf)
40. [Burchard et al. (2026b)](https://medical.berentx.com/wp-content/uploads/2026/05/APMRF2026-P02-Nonclinical.pdf)
41. [Burton et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34304992/)
42. [California Department of Health Care Access and Information Prescription Drugs Introduced to Market (2026)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22Manufacturer%20Name%22%2C%22NDC%20Number%22%2C%22Drug%20Product%20Description%22%2C%22Date%20Introduced%20to%20Market%22%2C%22WAC%20at%20Introduction%22%2C%22Estimated%20Number%20of%20Patients%22%2C%22Breakthrough%20Therapy%20Indicator%22%2C%22Priority%20Review%20Indicator%22%2C%22General%20Comments%22%20FROM%20%220e3afcfc-a5eb-41c6-a633-deaa2bfb5710%22%20WHERE%20%22NDC%20Number%22%20%3D%20%2783853010101%27)
43. [California Department of Health Care Access and Information Prescription Drugs Introduced to Market, MIPLYFFA (2026)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22Manufacturer%20Name%22%2C%22NDC%20Number%22%2C%22Drug%20Product%20Description%22%2C%22Date%20Introduced%20to%20Market%22%2C%22WAC%20at%20Introduction%22%2C%22Estimated%20Number%20of%20Patients%22%20FROM%20%220e3afcfc-a5eb-41c6-a633-deaa2bfb5710%22%20WHERE%20%22Drug%20Product%20Description%22%20LIKE%20%27Miplyffa%25%27)
44. [Cawley et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11893204/)
45. [ClinicalTrials.gov NCT00344331](https://clinicaltrials.gov/study/NCT00344331)
46. [ClinicalTrials.gov NCT01747135](https://clinicaltrials.gov/study/NCT01747135)
47. [ClinicalTrials.gov NCT02534844](https://clinicaltrials.gov/study/NCT02534844)
48. [ClinicalTrials.gov NCT02534844 API record](https://clinicaltrials.gov/api/v2/studies/NCT02534844)
49. [ClinicalTrials.gov NCT02534844 results](https://clinicaltrials.gov/study/NCT02534844?tab=results)
50. [ClinicalTrials.gov NCT03643562](https://clinicaltrials.gov/study/NCT03643562)
51. [ClinicalTrials.gov NCT03643562 API record](https://clinicaltrials.gov/api/v2/studies/NCT03643562)
52. [ClinicalTrials.gov NCT03643562 results](https://clinicaltrials.gov/study/NCT03643562?tab=results)
53. [ClinicalTrials.gov NCT03879655](https://clinicaltrials.gov/study/NCT03879655)
54. [ClinicalTrials.gov NCT03879655 results](https://clinicaltrials.gov/study/NCT03879655?tab=results)
55. [ClinicalTrials.gov NCT04860960](https://clinicaltrials.gov/study/NCT04860960)
56. [ClinicalTrials.gov NCT04958642](https://clinicaltrials.gov/study/NCT04958642)
57. [ClinicalTrials.gov NCT04958642 results](https://clinicaltrials.gov/study/NCT04958642?tab=results)
58. [ClinicalTrials.gov NCT05368038](https://clinicaltrials.gov/study/NCT05368038)
59. [ClinicalTrials.gov NCT07054515](https://clinicaltrials.gov/study/NCT07054515)
60. [CMS Clinical Laboratory Fee Schedule (2026)](https://www.cms.gov/files/zip/26clabq4.zip)
61. [Crumling et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5676048/)
62. [Department of Veterans Affairs Federal Supply Schedule pharmaceutical prices (2026)](https://www.va.gov/opal/docs/nac/fss/vaFssPharmPrices.xlsx)
63. [Diaz et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9438239/)
64. [Drugs.com Lembaz FDA approval history (2026)](https://www.drugs.com/history/lembaz.html)
65. [Drugs@FDA NDA 219132](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219132)
66. [Drugs@FDA NDA 220996](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220996)
67. [EMA orphan designation EU/3/13/1124 (2013)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1124)
68. [Erickson and Fiorenza (2017)](https://pubmed.ncbi.nlm.nih.gov/28803711/)
69. [European Medicines Agency Aqneursa EPAR (2026)](https://www.ema.europa.eu/en/medicines/human/EPAR/aqneursa)
70. [European Medicines Agency Meplyffa refusal (2026)](https://www.ema.europa.eu/en/medicines/human/EPAR/meplyffa)
71. [European Medicines Agency Meplyffa refusal questions and answers (2026)](https://www.ema.europa.eu/en/documents/smop-initial/questions-answer-refusal-marketing-authorisation-meplyffa-arimoclomol_en.pdf)
72. [European Medicines Agency Zavesca product information (2026)](https://www.ema.europa.eu/en/documents/product-information/zavesca-epar-product-information_en.pdf)
73. [Evans et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8600786/)
74. [Farhat et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8900058/)
75. [Farmer et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7448545/)
76. [Farmer et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12353886/)
77. [FDA (2024)](https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treat-niemann-pick-disease-type-c)
78. [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer)
79. [FDA Miplyffa approval announcement (2024)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-niemann-pick-disease-type-c)
80. [FDA NDA 220996 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220996Orig1s000ltr.pdf)
81. [FDA NDA approval letter (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/219132Orig1s000ltr.pdf)
82. [FDA Orphan Drug Designations and Approvals (2013)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=386412)
83. [Fierce Pharma LEMBAZ approval report (2026)](https://www.fiercepharma.com/pharma/beren-clinches-long-awaited-fda-nod-niemann-pick-disease)
84. [Fierce Pharma phase 3 results report (2026)](https://www.fiercepharma.com/pharma/intrabios-aqneursa-roll-eu-approval-races-toward-another-rare-disease-indication-phase-3-win)
85. [Freihuber et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10362619/)
86. [Garver et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17497724/)
87. [Gascón-Bayarri et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9726274/)
88. [GeneDx Zevra NPC sponsored genetic testing program press release (2026)](https://www.businesswire.com/news/home/20260310450068/en)
89. [Golden et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10200045/)
90. [Gutić et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36243834/)
91. [Hastings et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6805667/)
92. [Héron et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3465012/)
93. [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)
94. [ICER Launch Price and Access Report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_2026_Launch-Price-and-Access-Final-Report_ForPublication-1.pdf)
95. [Imrie et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19725798/)
96. [Jiang et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4076072/)
97. [Jiang et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5316294/)
98. [Jiang et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6365165/)
99. [Jiao et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Jiao_2026_NORD_Poster_Statistical-Methods_uploaded_QR_07OCT26_FINAL.pdf)
100. [Julich et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Julich_2026_CNS-Poster_Sibling-Case-Study_09Oct2026_Final-1.pdf)
101. [Kao et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7317750/)
102. [King et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3895917/)
103. [Koens et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5007743/)
104. [Labrecque et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8604933/)
105. [LEMBAZ billing and coding guide (2026)](https://lembazrx.com/wp-content/uploads/billing-coding-guide.pdf)
106. [LEMBAZ caregiver website (2026)](https://lembazrx.com/)
107. [LEMBAZ dosing and administration guide (2026)](https://lembazrx.com/wp-content/uploads/dosing-administration-guide.pdf)
108. [LEMBAZ Family Support terms and conditions (2026)](https://lembazrx.com/Co-Pay)
109. [LEMBAZ letter of medical necessity template (2026)](https://lembazrx.com/wp-content/uploads/medical-necessity-template.pdf)
110. [LEMBAZ patient enrollment form (2026)](https://lembazrx.com/wp-content/uploads/patient-enrollment-form.pdf)
111. [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)
112. [LEMBAZ prior authorization checklist (2026)](https://lembazrx.com/wp-content/uploads/prior-authorization-checklist.pdf)
113. [Maarup et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4633280/)
114. [Mallinckrodt Form 10-K (2019)](https://www.sec.gov/Archives/edgar/data/1567892/000156789219000009/mnk10-k122818.htm)
115. [Mallinckrodt Form 10-K (2020)](https://www.sec.gov/Archives/edgar/data/1567892/000156789220000005/mnk10-k122719.htm)
116. [Mallinckrodt plan of reorganization exhibit (2021)](https://www.sec.gov/Archives/edgar/data/1567892/000119312521264916/d41435dex993.htm)
117. [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)
118. [Mandos December 2021 community update (2021)](https://www.berentx.com/news/npc-community-update-december-2021/)
119. [Mandos expanded access program continuation letter (2021)](https://www.berentx.com/news/npc-expanded-access-program-continues-september-2021/)
120. [Mandos Health survival and biomarker analyses press release (2025)](https://www.berentx.com/news/adrabetadex-data-analyses-show-benefit-npc/)
121. [Mandos May 2022 community update (2022)](https://www.berentx.com/news/npc-community-update-may-2022/)
122. [Mandos November 2022 community update (2022)](https://www.berentx.com/news/npc-community-update-november-2022/)
123. [Matsuo et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5121362/)
124. [Matsuo et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38448301/)
125. [Medicaid.gov State Drug Utilization Data 2025 (2026)](https://data.medicaid.gov/api/1/datastore/query/158a1baa-5506-400a-8ec3-97756f0b0536/0?conditions%5B0%5D%5Bproperty%5D=ndc&conditions%5B0%5D%5Bvalue%5D=83853010101&conditions%5B0%5D%5Boperator%5D=%3D&conditions%5B1%5D%5Bproperty%5D=state&conditions%5B1%5D%5Bvalue%5D=XX&conditions%5B1%5D%5Boperator%5D=%3D&limit=20&properties%5B%5D=utilization_type&properties%5B%5D=state&properties%5B%5D=ndc&properties%5B%5D=year&properties%5B%5D=quarter&properties%5B%5D=suppression_used&properties%5B%5D=product_name&properties%5B%5D=units_reimbursed&properties%5B%5D=number_of_prescriptions&properties%5B%5D=total_amount_reimbursed&properties%5B%5D=medicaid_amount_reimbursed&properties%5B%5D=non_medicaid_amount_reimbursed&sorts%5B0%5D%5Bproperty%5D=quarter&sorts%5B0%5D%5Border%5D=asc&schema=false&keys=true&count=false)
126. [Medicaid.gov State Drug Utilization Data 2025 for MIPLYFFA (2026)](https://data.medicaid.gov/api/1/datastore/query/158a1baa-5506-400a-8ec3-97756f0b0536/0?conditions%5B0%5D%5Bproperty%5D=product_name&conditions%5B0%5D%5Bvalue%5D=MIPLYFFA%25&conditions%5B0%5D%5Boperator%5D=like&conditions%5B1%5D%5Bproperty%5D=state&conditions%5B1%5D%5Bvalue%5D=XX&conditions%5B1%5D%5Boperator%5D=%3D&limit=50&properties%5B%5D=utilization_type&properties%5B%5D=ndc&properties%5B%5D=product_name&properties%5B%5D=year&properties%5B%5D=quarter&properties%5B%5D=suppression_used&properties%5B%5D=units_reimbursed&properties%5B%5D=number_of_prescriptions&properties%5B%5D=total_amount_reimbursed&sorts%5B0%5D%5Bproperty%5D=ndc&sorts%5B0%5D%5Border%5D=asc&sorts%5B1%5D%5Bproperty%5D=quarter&sorts%5B1%5D%5Border%5D=asc&schema=false&keys=true&count=false)
127. [Medicaid.gov State Drug Utilization Data 2026 (2026)](https://data.medicaid.gov/api/1/datastore/query/2957a7f9-9a15-453e-9afd-3bbdcbac8fd3/0?conditions%5B0%5D%5Bproperty%5D=ndc&conditions%5B0%5D%5Bvalue%5D=83853010101&conditions%5B0%5D%5Boperator%5D=%3D&conditions%5B1%5D%5Bproperty%5D=state&conditions%5B1%5D%5Bvalue%5D=XX&conditions%5B1%5D%5Boperator%5D=%3D&limit=20&properties%5B%5D=utilization_type&properties%5B%5D=state&properties%5B%5D=ndc&properties%5B%5D=year&properties%5B%5D=quarter&properties%5B%5D=suppression_used&properties%5B%5D=product_name&properties%5B%5D=units_reimbursed&properties%5B%5D=number_of_prescriptions&properties%5B%5D=total_amount_reimbursed&properties%5B%5D=medicaid_amount_reimbursed&properties%5B%5D=non_medicaid_amount_reimbursed&sorts%5B0%5D%5Bproperty%5D=quarter&sorts%5B0%5D%5Border%5D=asc&schema=false&keys=true&count=false)
128. [Medicaid.gov State Drug Utilization Data 2026 for MIPLYFFA (2026)](https://data.medicaid.gov/api/1/datastore/query/2957a7f9-9a15-453e-9afd-3bbdcbac8fd3/0?conditions%5B0%5D%5Bproperty%5D=product_name&conditions%5B0%5D%5Bvalue%5D=MIPLYFFA%25&conditions%5B0%5D%5Boperator%5D=like&conditions%5B1%5D%5Bproperty%5D=state&conditions%5B1%5D%5Bvalue%5D=XX&conditions%5B1%5D%5Boperator%5D=%3D&limit=50&properties%5B%5D=utilization_type&properties%5B%5D=ndc&properties%5B%5D=product_name&properties%5B%5D=year&properties%5B%5D=quarter&properties%5B%5D=suppression_used&properties%5B%5D=units_reimbursed&properties%5B%5D=number_of_prescriptions&properties%5B%5D=total_amount_reimbursed&sorts%5B0%5D%5Bproperty%5D=ndc&sorts%5B0%5D%5Border%5D=asc&sorts%5B1%5D%5Bproperty%5D=quarter&sorts%5B1%5D%5Border%5D=asc&schema=false&keys=true&count=false)
129. [Medscape adrabetadex drug monograph (2026)](https://reference.medscape.com/drug/lembaz-adrabetadex-4000605)
130. [Mengel et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7684888/)
131. [Mengel et al. (2021a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9293014/)
132. [Mengel et al. (2021b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8611877/)
133. [Mengel et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12166820/)
134. [Mengel et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40663813/)
135. [Mengel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13310637/)
136. [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)
137. [Modin et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8470073/)
138. [Nafees et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13702622/)
139. [New York State Medicaid eMedNY](https://www.emedny.org/info/formfile.aspx)
140. [New York State Medicaid list of reimbursable drugs (2026)](https://docs.emedny.org/ReimbursableDrugs/MedReimbDrugsFormulary.csv)
141. [NHS England Specialised Services Quality Dashboard lysosomal storage disorders metric definitions (2022)](https://www.england.nhs.uk/wp-content/uploads/2022/04/Lysosomal-Storage-Disorders-LSD-All-Ages.pdf)
142. [NICE arimoclomol appraisal (2022)](https://www.nice.org.uk/guidance/indevelopment/gid-hst10037)
143. [NICE VTS-270 appraisal (2026)](https://www.nice.org.uk/guidance/discontinued/gid-hst10020)
144. [NICHD phase 1-2a trial news release (2017)](https://www.nichd.nih.gov/newsroom/releases/nieman_pick_080917)
145. [Oklahoma Health Care Authority Drug Utilization Review Board packet (2025)](https://oklahoma.gov/content/dam/ok/en/okhca/docs/about/boards-and-committees/dur/2025/march/03122025%20DUR%20Packet.pdf)
146. [Ontario Exceptional Access Program Zavesca reimbursement guidelines (2011)](https://files.ontario.ca/moh-reimbursement-guidelines-zavesca.pdf)
147. [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf)
148. [Orphazyme complete response letter announcement (2021)](https://www.sec.gov/Archives/edgar/data/1764791/000156459021033445/orph-ex991_6.htm)
149. [Ory et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176479/)
150. [Ottinger et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4048128/)
151. [Padilla et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11970998/)
152. [Patterson et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17689147/)
153. [Patterson et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/19822772/)
154. [Patterson et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4462071/)
155. [Patterson et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7540716/)
156. [Patterson et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7183679/)
157. [Patterson et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7881637/)
158. [Patterson et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12296777/)
159. [Pharmaphorum LEMBAZ approval report (2026)](https://pharmaphorum.com/news/berens-niemann-pick-drug-lembaz-cleared-fda)
160. [Pineda et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4957867/)
161. [Porter et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12638010/)
162. [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf)
163. [Rafael Holdings Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026113659/ea0309115-10k_rafael.htm)
164. [Rafael Holdings investor presentation (2026)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026117552/ea031154001ex99-1.htm)
165. [Rafael Holdings TransportNPC topline results release (2026)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026104876/ea030712501ex99-1.htm)
166. [Roch Santed et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6451626/)
167. [Rodriguez-Gil et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800820/)
168. [Scottish Medicines Consortium (2010)](https://scottishmedicines.org.uk/medicines-advice/miglustat-zavesca-nonsubmission-63210/)
169. [Sharma et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10475848/)
170. [Sharma et al. (2026)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2026/poster-session-3-4/economic-perspectives-on-niemann-pick-disease-a-targeted-review-of-economic-evidence)
171. [Sidhu et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7145728/)
172. [Solomon et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7489403/)
173. [Solomon et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13539892/)
174. [Sucampo Vtesse acquisition press release (2017)](https://www.sec.gov/Archives/edgar/data/1365216/000117184317001888/exh_991.htm)
175. [Tchan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193484/)
176. [Texas Department of State Health Services 2025 Annual WAC Report (2026)](https://www.dshs.texas.gov/sites/default/files/CP-TexasRX/files/2025-annual-wac-report_0226.xlsx)
177. [Texas Department of State Health Services 2026 Annual WAC Report (2026)](https://www.dshs.texas.gov/sites/default/files/CP-TexasRX/files/2026-annual-wac-report_1026.xlsx)
178. [Texas Department of State Health Services Prescription Drug Price Disclosure Program data overview](https://www.dshs.texas.gov/prescription-drug-price-disclosure-program/data-overview)
179. [van Karnebeek et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25095726/)
180. [Vanier (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2902432/)
181. [Vite et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4415615/)
182. [Vtesse Breakthrough Therapy designation press release (2016)](https://www.biospace.com/b-vtesse-inc-b-announces-fda-s-granting-of-breakthrough-therapy-designation-for-vts-270-in-niemann-pick-type-c1-disease)
183. [Vtesse VTS-270-302 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/55/NCT03879655/Prot_SAP_001.pdf)
184. [Vtesse VTS301 protocol amendment 15 (2021)](https://cdn.clinicaltrials.gov/large-docs/42/NCT04958642/Prot_000.pdf)
185. [Vtesse VTS301 protocol synopsis (2019)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/Prot_000.pdf)
186. [Vtesse VTS301 statistical analysis plan (2018)](https://cdn.clinicaltrials.gov/large-docs/44/NCT02534844/SAP_001.pdf)
187. [Walterfang et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3552828/)
188. [Wassif et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4486368/)
189. [Wraith et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20045366/)
190. [Yanjanin et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2798912/)
191. [Yergey et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5393605/)
192. [YODA Project data request 2021-4741](https://yoda.yale.edu/data-request/2021-4741)
193. [ZAVESCA prescribing information (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021348s016lbl.pdf)
194. [Zevra Therapeutics advisory committee release (2024)](https://www.biospace.com/fda-advisory-committee-votes-favorably-that-the-data-support-arimoclomol-as-effective-treatment-for-patients-with-niemann-pick-disease-type-c)
195. [Zevra Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000011/zvra-20251231.htm)
196. [Zevra Therapeutics third quarter 2026 results release (2026)](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000085/zvra-20261103xex991earnings.htm)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
